Of note, while the tumor size, portal vein invasion, and AFP level were associated with OS and PFS, these factors were not significant predictors of extrahepatic progression in the present study, suggesting that in advanced HCC, the tumor burden in the liver itself is unrelated to extrahepatic progression after TACE treatment. This evidence concerns the gene AFP and hepatocellular carcinoma.